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Epidemiology and clinical characteristics of invasive 
Group A streptococcal infections (IGASI) are highly 
variable. Long-term studies are needed to understand 
the interplay between epidemiology and virulence. In 
a population-based study of IGASI in Iceland from 1975 
to 2012, 288 cases were identified by positive cultures 
from normally sterile body sites. Charts were reviewed 
retrospectively and emm-types of viable Streptococcus 
pyogenes isolates (n=226) determined. Comparing the 
first and last decade of the study period, IGASI inci-
dence increased from 1.09 to 3.96 cases per 100,000 
inhabitants per year. The most common were emm 
types 1 (25%), 28 (11%) and 89 (11%); emm1 strains 
were most likely to cause severe infections. Infections 
in adults were significantly more likely to be severe 
during the seasonal peak from January to April (risk 
ratio: 2.36, 95% confidence interval: 1.34–4.15). 
Significant seasonal variability in severity was noted 
among patients with diagnosis of sepsis, respiratory 
infection and cellulitis, with 38% of severe infections 
in January to April compared with 16% in other months 
(p<0.01). A seasonal increase in severity of IGASI sug-
gested that generalised seasonal increase in host sus-
ceptibility, rather than introduction of more virulent 
strains may play a role in the pathogenesis of these 
potentially fatal infections.
Introduction
Streptococcus pyogenes, or Lancefield group A 
Streptococcus (GAS), is known for its ability to cause 
diverse clinical manifestations, including soft tissue 
infections, pneumonia, and toxic shock syndrome. 
Over the past 30 years there has been a concern about 
increasing incidence and severity of invasive group A 
streptococcal infections (IGASI) [1-3], defined as infec-
tions associated with the isolation of the bacteria from 
a normally sterile body site. GAS has many virulence 
factors; a key factor is the M protein of the cell wall 
for which more than 100 different types are known [4]. 
Sequencing of the emm gene and classification of the 
M protein is often used to characterise GAS isolates [5] 
with studies from the United States (US) and Europe 
showing that isolates with M types 1, 3, 4, 6 and 28 
cause about 50% of IGASI [6-8].
IGASI are often life-threatening; The most severe 
clinical presentations are necrotising fasciitis (NF), 
an aggressive and rapidly destructive infection of 
deep subcutaneous tissue and fascia, characterised 
by necrosis of skin and underlying structures, and 
streptococcal toxic shock syndrome (STSS), defined as 
streptococcal infection associated with sudden shock 
and organ failure [3,9]. Certain risk factors for invasive 
infections have been established such as the extremes 
of age, immunosuppression, diabetes mellitus and 
loss of skin integrity [10,11]. The factors driving the 
increased incidence of IGASI are not completely under-
stood, however, clinical and microbiological studies 
demonstrate a complex epidemiology with great spati-
otemporal variation of this common pathogen. 
It is well established that the incidence of GAS infec-
tions can fluctuate in time, both seasonally and over 
the course of several years. However, most published 
studies on IGASI are limited by a relatively short obser-
vation period. Studies have shown, with remarkable 
congruence between countries, an interesting sea-
sonal pattern of non-invasive and invasive infections, 
with the incidence being high in the months January 
to March but low in late summer and autumn [12,13]. A 
large European study showed that several emm types 
had a uniform seasonal prevalence whereas other 
types exhibited more fluctuations [14]. Little is known 
about whether severity of infection varies seasonally.
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The purpose of this study was two-fold: Firstly, to pro-
vide a long term nationwide analysis of IGASI in Iceland 
by using clinical and population-based data to assess 
epidemiology, clinical characteristics, therapy and out-
come. Secondly, to study seasonal variations in the 
incidence, severity, and clinical presentation of IGASI 
and the relationship to emm type prevalence. 
Methods
Setting and case definition
We conducted a nationwide study of IGASI diagnosed 
in Iceland from 1 January 1975 to 31 March 2012.  A 
case of IGASI was defined as isolation of GAS from a 
normally sterile body site, or isolation of the organism 
from a non-sterile site, in conjunction with the diagno-
sis of STSS or NF. Cases were identified through micro-
biology databases and hospital discharge diagnosis 
using the appropriate ICD codes (ICD-9 number (period 
1983–96): 728.0; ICD-10 numbers (period 1997–2005): 
A48.3; M60.0; M63.0; M63.2). Using these criteria, 
288 cases were identified and for these, 275 records 
were retrieved and reviewed retrospectively (yield: 
96%), but age and vital status was known for all 288 
cases. Cases were defined as severe, if their condi-
tion required admission to intensive care and/or if 
the patient died from the infection during hospitalisa-
tion. The study was approved by the Icelandic National 
Bioethics Committee, by the Data Protection Authority 
of Iceland, and by the responsible Chief Medical 
Officer at healthcare facilities where clinical data were 
obtained. 
Data collection
Data collected included age, sex, past medical history, 
medication, presenting symptoms, physical findings, 
and laboratory results upon admission and treatment. 
The main antibiotic treatment was defined as the anti-
biotic used for at least half of the treatment duration. 
Microbiology and emm typing
During the first 15 years of the study, a Bactec (Becton 
Dickinson Microbiology Systems) radiometric system 
was most widely used. During 1990–2001, Bactec 
(Becton Dickinson), ESP (Difco) and bioMérieux Vital 
(bioMérieux) nonradiometric systems were used. The 
BacT/Alert system (bioMérieux) was used from 2002 
[15,16]. Invasive specimens, except blood cultures, 
were inoculated on blood agar and chocolate agar 
plates (Difco) and incubated under a humidified atmos-
phere containing 5% CO2, as well as anaerobically for 
24 hr. All positive blood culture bottles showing Gram-
positive streptococci were inoculated in the same man-
ner. All isolates were kept in Trypticase Soy Broth (TSB; 
Becton Dickinson) containing 20% glycerol and stored 
at −80°C. The emm-typing of isolates was performed 
according to the protocols and recommendations of the 
US Centers for Disease Control and Prevention (CDC)
[17], and the first 240 bases of each sequence were 
searched against the emm CDC database [4]. Identity 
of at least 95% with previously described sequences 
over the first 150 bases considered allowed the assign-
ment of an emm type. Sequencing was done by the 
Sanger method using an Applied Biosystems 3730xl 
DNA Analyzer. Subtyping was not performed.
Statistical analysis
The national population registry was used to calculate 
incidence and age-specific incidence rates (population 
data available at Statistic Iceland [18]). The crude in-
house and 30-day mortality was assessed using hospi-
tal records and the national population registry. 
Comparison of categorical variables was performed 
using Fisher s´ exact test and Pearson s´ test using 
SPSS, version 10.5. Level of significance was set at 
p<0.05, and all tests were two-tailed. Risk ratios or 
incidence rate ratios and their associated 95% confi-
dence intervals (CI) were calculated using log-linked 
models (Poisson or binomial distribution, as appropri-
ate) in PROC GENMOD (SAS v9.2). Dummy variables 
were used to test the risk or incidence during a given 
time period with the noted reference time period. We 
also considered whether influenza activity was associ-
ated with increased GAS incidence. To do this, we fit 
a Poisson regression where the outcome was monthly 
GAS cases, and included predictors for linear trend, 
monthly indicator variables for the winter months and 
influenza epidemic periods [19]. Influenza epidemic 
periods were defined as month when influenza activ-
ity was significantly above a harmonic seasonal base-
line, determined using Serfling regression [20]. We 
included data between 1985 and 2008 for the influenza 
analyses.
Results
Epidemiology
From 1 January 1975 to 31 March 2012, 288 cases of 
IGASI were identified, including 54 children (≤16 years-
old) and 234 adults. There were slightly more female 
(54%) than male cases. The number of cases diagnosed 
by six-year intervals is shown in Figure 1A. The inci-
dence during 1975 to 1986 was 1.09 cases per 100,000 
inhabitants per year and rose to 3.08 and 3.96 cases 
per 100.000 inhabitants per year during 1987 to 1998 
and 1999 to 2010, respectively (rate ratios: 2.82; 95% 
CI: 1.87–4.25 and 3.63; 95% CI: 2.45–5.38). Figure 1B 
shows the age-specific incidence rates for both halves 
of the study, 1975 to 1993 and 1994 to 2012, highlight-
ing an increase in most age groups during the second 
half, which is not explained by difference in age com-
position between study periods. The age-specific inci-
dence was highest at both extremes of age (Figure 1B). 
Clinical characteristics
In this retrospective study 162 of the 231 evaluable 
cases, had at least one underlying medical condi-
tion recorded, including cardiovascular disease in 59, 
malignancy in 34, respiratory disease in 28, diabetes 
mellitus in 12 and alcohol and/or substance abuse in 
14 of the 231. In five cases, the infection was linked 
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to illicit intravenous drug use. No patient had under-
lying human immunodeficiency virus (HIV) infection in 
our cohort, whereas five children had chickenpox. Drug 
information prior to admission was available for 198 
patients, of whom 19 were receiving immunosuppres-
sive therapy and eight had received antibiotics before 
admission; there was documented non-steroidal anti-
inflammatory drug (NSAID) usage prior to admission in 
25 patients. 
The association between age, clinical characteristics 
and outcome (severe and non-severe) is shown in Table 
1. Skin/soft tissue infections were the most common 
manifestation, diagnosed in 33% of the cases, fol-
lowed by sepsis in 24%. Puerperal sepsis was diag-
nosed in eight women and three children. STSS and 
NF were diagnosed in 11% of the cases, and there was 
an increase in the number of STSS and NF cases diag-
nosed during the study period, with only four cases 
documented from 1975 to 1994, compared with 10 
cases from 1995 to 2004 and 18 cases from 2005 to 
2012.
Therapy and outcome
The most common treatment was a beta-lactam anti-
biotic (208/219), usually penicillin. In severe infections 
Figure 1
Epidemiology of invasive Group A streptococcal infection in Iceland
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Blue bars: incidence rates for the first half of the study; red bars: incidence rates for second half. 
The incidence almost doubled in almost all age groups.
The incidence during 1975–86 was 1.09 cases/100,000 inhabitants/year and rose to 3.96 cases/100,000 inhabitants/year during 1999–2010. 
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Table 1
Age-specific incidence per 100,000 per year, clinical syndrome and severitya of invasive Group A streptococcal infections in 
Iceland, 1975–2012 (n=288) 
Syndrome
Age (years)
0–9 10–19 20–29 30–39 40–49 50–59 60–69 70–79 ≥80
Arthritis 0.26 0  0.06 0.14 0.16 0.30 0.55 0.60 0.75 
Skin/soft 
tissue 0.49 0.18 0.31 0.35 0.73 1.31 2.06 3.20 7.93 
Othera 0.43 0 0.06 0.07 0.16 0.40 1.10 2.40 2.24 
Respiratory 
tract infection 0.31 0.06 0 0.07 0 0.20 0.27% 1.00 2.61 
Sepsis 1.22 0.12 0.31 0.42 0.40 0.71 1.37 2.20 2.20
STSS 0.06 0 0.19 0.14 0.16 0.71 0.41 0.40 0
NF 0 0 0 0.21 0 0.30 0.41  0 1.12 
NF: necrotising fasciitis; STSS: streptococcal toxic shock syndrome.
a The category “Other” includes bacteraemia with unclear focus of infection (14 cases), osteomyelitis (five cases) and upper respiratory 
infection (seven cases). It also includes 18 cases for whom information other than culture data, age, sex and vital status was unknown. 
Figure 2
Distribution of emm types during the study period, Iceland, 1975–2012 (n=226 cases)
For 2012, the first three months are included.
The emm types showed much fluctation in prevalence during the study period.
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(n=83), other drugs were used in combination, most 
commonly clindamycin (27/219), followed by aminogly-
cosides (27/219). The average length of parenteral anti-
biotic treatment was 11.9 days. During the study period, 
77 of the 256 patient for whom we had this informa-
tion were admitted to an intensive care unit (ICU), 56 of 
them needed inotropic drugs, 28 required mechanical 
ventilation and 10 received dialysis for renal failure.
The crude 30-day mortality was 13.4% in adults and 
5.6% in children. STSS or NF was associated with a 
significantly higher mortality rates than other infec-
tions in adults (29% vs 11%; risk ratio: 2.68; 95% CI: 
1.36–5.27). 
emm types
Overall 25 different emm types were identified among 
the 226 viable isolates that were recovered between 
1987 and 2012. Figure 2 shows the emm types obtained 
during the study period. Table 2 shows the distribution 
of emm types in children compared with adults. The 
most common types were emm1 (25%), 28 (11%), 89 
(11%), 3 (9%), 12 (8%). Among the 25 cases (10 female, 
15 male), no child was diagnosed with emm28, and only 
one case of puerperal sepsis was caused by emm28. 
The association between clinical presentation, emm 
types, and severity is summarised in Table 3. Patients 
infected by emm 1-type strains, compared with all 
other emm types identified, were more likely to have 
severe disease (p<0.03), whereas patients with emm89 
had a  less severe course of disease, required intensive 
care less frequently and had no fatalities (p=0.05). In 
addition, the severity differed greatly by clinical pres-
entation, with NF (4 of 12 cases) and STSS (6 of 20 
cases) being associated with a fatal outcome in 31% of 
cases. Invasive respiratory tract infection (4/23 cases) 
and sepsis (12/69 cases) were associated with a fatal 
outcome in 17% of cases. All cases linked to illicit 
intravenous drug use were caused by different emm 
types. Puerperal sepsis was caused by emm type 1 in 
six cases and emm types 3, 4, 28, 77, 89 in one case 
each. Clinical syndromes of cellulitis and arthritis were 
associated with least mortality, three of 95 and 0 of 22 
cases, respectively. 
Seasonality of incidence and severity of invasive 
Group A streptococcal infection
There was significant seasonal variation in the inci-
dence of IGASI (Figure 3). The association between 
incidence by month and clinical presentation is given 
in Figure 3A, demonstrating that the diagnoses of sep-
sis, NF and STSS were more common in mid- to late 
winter with nine of 12 NF cases and eight of 20 STSS 
cases diagnosed during January to April. Figures 3B 
and 3C show the incidence by severity and month of 
diagnosis in children and adults, respectively. The inci-
dence peaked in late winter and early spring, specifi-
cally in January to February for children, and in April 
for adults. No seasonal variation in severity was noted 
among children, but the group was small with relatively 
few fatalities. Among adults, cases of IGASI were sig-
nificantly more likely to be severe (resulting in death or 
ICU admission) during the seasonal peak in January to 
April than in the period June to September (Figure 3C) 
(risk ratio: 2.36, 95%CI: 1.34-4.15). No association was 
found between IGASI and influenza epidemic period. 
The number of cases occurring per season in this study 
may be insufficient to detect such an increase above 
the seasonal baseline.
It is possible that the seasonal variations in severity 
were simply a result of differing clinical presentations 
during the peak months, so we examined the indi-
vidual seasonal variations in severity of those with a 
diagnosis of sepsis, respiratory infections, or cellulitis 
(excluding NF and STSS patients and arthritis or other 
clinical manifestations due to small numbers). There 
was significant seasonal variability in severity among 
these cases, with 38% of severe infections in January 
Table 2
Streptococcus pyogenes emm types identified during the 
study period, Iceland, 1975–2012 (n=226 cases)
emm type children adults total p value
1 12 47 59 0.85
2 1 5 6 1.00
3 3 18 21 0.84
4 6 7 13 0.04
5 0 3 3 1.00
6 3 3 6 0.16
8 0 4 4 0.87
9 0 1 1 1.00
11 0 2 2 1.00
12 6 11 17 0.15
22 5 6 11 0.07
28 0 25 25 <0.01
43 0 1 1 1.00
58 0 1 1 1.00
75 0 8 8 1.00
77 0 3 3 1.00
81 0 3 3 1.00
84 0 1 1 1.00
85 0 1 1 1.00
87 1 5 6 1.00
89 1 24 25 0.06
94 1 4 5 1.00
102 0 1 1 1.00
110 0 2 2 1.00
118 0 1 1 1.00
Unknown 15 47 62 0.29
Total 54 234 288
Overall, 226 (74%) of invasive isolates (dating from 1987 to 2012) 
were available for emm sequencing. The most common emm 
types were 1, 28 and 89 which comprised nearly half of all the 
cases. As shown, emm type 4 was significantly more common 
among children (p=0.04), whereas emm 28 was seen solely 
among adults (p=0.01). 
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to April compared with 16% of severe infections in 
other months (p<0.01). There was also significant sea-
sonal variation in the severity of arthritis and non-
focal infections: 32% were severe in January to April 
compared with 5% during the rest of the year (p<0.05). 
There were too few cases of non-severe NF and STSS 
to evaluate seasonal variations. Analyses of adults 
infected with emm type 1 showed that 75% of cases 
were severe in January to April compared with 37.5% in 
June to September, but this difference was not statisti-
cally significant (p=0.09, Fisher’s exact test). 
Discussion
We present a long-term population-based study of 
IGASI in Iceland, a setting where these infections are 
frequent compared with other Western developed 
nations. The study had a long observation period, and 
clinical as well as microbiological data were analysed. 
The incidence of IGASI varies greatly by geographical 
location. Published studies from Europe show an inci-
dence in northern European countries of 2.5 to 3.1 per 
100.000 inhabitants per year in Finland, Denmark and 
Norway [6,7], which is within the range of the estimates 
presented here. During the last decade, the incidence 
rate in our study was 3.96 per 100.000 inhabitants per 
year, i.e. even higher than corresponding figures from 
other Nordic countries [6,7,13]. The results are also in 
accordance with other reports, which show an increase 
starting in the 1980s [21]. Currently, the global number 
of IGASI is estimated to be 663,000 new cases and 
163,000 deaths each year, which is higher than that 
caused by measles [21,22]. 
The reasons for the increased incidence are not yet 
entirely clear. In the first decade of the current study, 
more sensitive blood culture methods as well as 
improved access to these diagnostic tools may have 
played a role in improved detection. Such technical 
explanations are less plausible for the last 15 to 20 
years of the study, when potential technical confound-
ers have remained fairly unchanged. Another possible 
explanation is the periodic introduction of new, more 
virulent GAS strains, possibly carrying novel M pro-
teins on their surface, for which there may be low herd 
immunity.
Our results show a higher age-specific incidence in the 
age groups under 10 and over 60 years-old, which is in 
agreement with other studies [2,13], probably reflecting 
the relative lack of sufficient immune responses at the 
extremes of age. Similarly, the most common clinical 
presentation is soft tissue infection followed by sep-
sis or bacteraemia without identified focus, which is in 
agreement with other studies [2,13,23]. Interestingly, 
there was a trend of more severe infections in the latter 
half of the study; the number of cases with NF and STSS 
almost doubled between 1995 to 2004 and 2005 to 
2012, although the second interval was shorter. Other 
investigators have shown that 58–67% of individuals 
with IGASI have at least one underlying disease [11]. 
Malignancies, cardiovascular diseases, diabetes and 
alcoholism are most frequently implicated, and this 
is borne out by the current study. Chickenpox is also 
strongly associated with invasive bacterial super-infec-
tion with GAS [10]; only five children had chickenpox in 
our cohort, precluding meaningful calculations of the 
relative risk for GAS infections following chickenpox. 
Table 3
Clinical manifestations associated with invasive Group A streptococcal infection and emm types, Iceland, 1975–2012 (n=226 
cases)
Syndrome emm 1 emm 28 emm 89 emm 3 emm 12 Other emm types 
emm type 
unknown Total Fatal 
ICU and/or 
fatal
Arthritis 2 1 4 0 2 10 3 22 (7.6%) 0 (0%) 3 (13.6%)
Skin/soft 
tissue 5 9 10 6 8 27 30 95 (33.0%) 3 (3.2%) 7 (7.4%)
Other 10 3 5 5 2 11 11 47 (16.3%) 5 (10.6%) 11 (23.4%)
Respiratory 
tract infection 9 3 0 3 1 3 4 23 (8.0%) 4 (17.4%) 13 (56.5%)
Sepsis 22 8 2 6 3 17 11 69 (24.0%) 12 (17.4%) 24 (34.8%)
STSS 8 1 2 1 0 5 3 20 (6.9%) 6 (30.0%) 20 (100%)
NF 3 0 2 0 1 6 0 12 (4.2%) 4 (33.3%) 11 (91.7%)
Total 59 25 25 21 17 79 62 288 34 89
Fatal 12 (20.3%) 4 (16.0%) 0 (0%) 2 (9.5%) 2 (11.8%) 6 (7.6%) 8 (12.9%)
ICU and/or 
fatal 27 (45.8%) 8 (32.0%) 6 (24.0%) 7 (33.3%) 3 (17.6%) 21 (26.6%) 11 (17.7%)
ICU: intensive care unit; NF: necrotising fasciitis; STSS: streptococcal toxic shock syndrome.
The clinical presentation of emm 1, the most common emm type (25% of isolates), was in over 50% of cases sepsis, STSS and NF, while emm 
28 (11% of isolates), 89 (11% of isolates) and 12 (8% of isolates) more often caused soft tissue infections. 
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Figure 3
Seasonality, clinical manifestations and severity of invasive infections by Group A Streptococci in Iceland, 1975–2011 (n=285)
NF: necrotising fasciitis; STSS: streptococcal toxic shock syndrome.
       
A. The more aggressive cases (STSS, NF, sepsis) cluster in mid- to late winter. 
B. The incidence reached a peak in January to February, but the severity was low in most cases, with no significant difference between winter 
and summer months (18% severe in summer vs 17% in winter). 
C. The incidence peaked in April, with significant seasonal increase in severity, as defined as admission to intensive care and/or death.  
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The antibiotic treatment did not change during the 
study period. Penicillin is still the drug of choice in the 
treatment of streptococcal infections, with the addi-
tion of clindamycin in cases of STSS or NF and possibly 
intravenous immunoglobulin in  select  circumstances. 
No patient in this cohort received immunoglobulin.
In this study, the overall fatality was significantly 
higher among patients who developed STSS or NF. This 
is consistent with results from previous studies, includ-
ing a study conducted in Sweden in 2002 to 2004 and 
a large European study in which 11 nations participated 
in the years 2003 and 2004 [11,13]. Almost half of all 
fatalities occurred within the first 48 hours of admis-
sion. These results are comparable to that of another 
study [24], emphasising the importance of early recog-
nition and treatment.
A GAS clone carrying the M1 (emm1) surface protein 
was first identified in the mid-1980s and associated 
with resurgence of serious streptococcal infections 
[25]. The M protein, encoded by emm, is a fimbrial pro-
tein located on the cell surface and an important viru-
lence factor with anti-phagocytic properties. On the 
other hand, the risk of severe IGASI may also be deter-
mined in part by the genetic susceptibility of the host 
[26,27]. Over a 25-year period, 25 different emm types 
were identified in Iceland. This emm distribution found 
in the current study was similar to that found in other 
Nordic countries [6,7]. In our cohort, emm4 was signifi-
cantly more common among children, whereas emm28 
was seen solely among adults. The reason for this dis-
crepancy between children and adults is unclear but 
may be reflective of differences in specific immunity 
between age groups. In Europe, the most prevalent 
emm types in adults are, in descending order, emm1, 
emm28, emm3 and emm89; also in children, emm1 is 
the most common isolate, followed by emm12, emm4, 
emm3 and emm28 [14]. 
The study of associations between emm types and 
clinical manifestations is challenging due to the vast 
number of circulating emm types. Spread of otherwise 
uncommon emm types among disadvantaged popula-
tions has been well described [28,29]. There are indi-
cations that cellulitis may more often be caused by 
emm87, emm83 or emm81, whereas STSS and NF have 
been linked to emm1 and puerperal sepsis to emm28 
[11,14]. Our study did suggest a significant association 
between infections caused by emm1 and severe dis-
ease, whereas patients with emm89 and 12 had less 
severe disease courses. The reasons why certain emm 
types are capable of causing more severe disease is 
unknown, but may be related to their associations with 
yet another virulence trait, such as production of SpeA, 
SpeZ and SpeJ exotoxins [30]. However, no correlation 
between clinical manifestations and a single superan-
tigen gene in GAS has been found [11]. 
Seasonality of pharyngitis and invasive disease caused 
by GAS has been documented previously. Studies have 
shown, with remarkable congruence between coun-
tries, that the overall incidence of invasive infections 
varies by month [2,13]. We also observed significant 
seasonal variation, with the incidence among adults 
being highest in March and April. Underlying causes 
of seasonality are incompletely understood, but expla-
nations such as preceding viral infections and sea-
sonal changes in behavioural patterns, e.g. increased 
in-door activities during winter, have been proposed 
as potentially increasing the likelihood of transmis-
sion [2,13]. The similarity between countries may also 
be suggestive of an environmental factor occurring in 
several countries at the same time, such as decrease 
in sunlight and possibly simultaneous increased 
host susceptibility [31]. In support of this theory, we 
observed an association between severity of IGASI and 
seasonality, with a higher proportion of severe cases 
in January to April compared with the average in June 
to September. Another study from the United Kingdom 
[24] had also demonstrated a seasonal difference in 
case severity, with more severe infections diagnosed 
in January. 
The seasonal variation that was noted here does corre-
spond very closely to the traditional influenza season 
in Iceland [19]. In addition, concurrent infections with 
influenza and GAS have been reported, with an appar-
ent increase in mortality when compared with influ-
enza alone [32]. However, we tested for, but did not 
detect, an association between IGASI in Iceland and 
the influenza epidemic period. The number of cases 
occurring per season in this study may be insufficient 
to detect such an increase above the seasonal base-
line. This is in contrast to a previous Canadian study 
which showed an association with Influenza B, which 
accounted for about 8% of the incidence of IGASI over 
any effect associated with modelled seasonal and 
long-term trends [33]. 
Seasonal variation in vitamin D levels has been pro-
posed to affect immune function [34]. Indeed, previous 
work from Iceland has shown that vitamin D levels are 
lowest in February to March and highest in June to July 
[35]. Thus, it would be interesting to investigate fur-
ther the impact vitamin D level has on severity of GAS 
infections. An alternate hypothesis of introduction of 
more virulent strains during the winter months was not 
borne out by our data, seeing as cases with emm1 type 
were more severe in winter than in summer. Likewise, 
the proportion of emm1 types among all adult disease 
isolates was comparable in winter (22%) and summer 
(15%). 
In summary, GAS remains a major public health con-
cern, with this pathogen showing great variability over 
time in incidence and clinical presentation. In this long-
term, nationwide study, we show a seasonal increase 
in disease severity in patients with sepsis, respiratory 
infections or cellulitis caused by GAS during January 
9www.eurosurveillance.org
to April compared with other months. This pattern was 
also evident in patients with invasive arthritis and non-
focal infections, suggesting that a generalised sea-
sonal increase in host susceptibility may play a role in 
the pathogenesis of these common, severe infections.
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